CN100594029C - Medicinal composition for injections in articular cavity - Google Patents
Medicinal composition for injections in articular cavity Download PDFInfo
- Publication number
- CN100594029C CN100594029C CN200610103473A CN200610103473A CN100594029C CN 100594029 C CN100594029 C CN 100594029C CN 200610103473 A CN200610103473 A CN 200610103473A CN 200610103473 A CN200610103473 A CN 200610103473A CN 100594029 C CN100594029 C CN 100594029C
- Authority
- CN
- China
- Prior art keywords
- chondroitin sulfate
- pharmaceutical composition
- molecular weight
- concentration
- hyaluronate sodium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides a pharmaceutical composition used for intra-articular injection, the main ingredients of which are sodium hyaluronate and chondroitin sulfate, wherein, the molecular weight of the sodium hyaluronate is 1.2 million to 5 million Daltons and the concentration is 0.5 percent to 2.0 percent, and the molecular weight of the chondroitin sulfate is 2000 to 15000 Daltons andthe concentration is 1 percent to 5 percent. The present invention has the advantages of good viscoelasticity and good buffer capacity of the sodium hyaluronate with relatively high molecular weight,as well as the advantages of rapid absorption and rapid repair of the chondroitin sulfate with relatively low molecular weight, thus the invention can be used for treating the arthritis by intra-articular injection.
Description
Technical field:
The invention belongs to medical technical field, a kind of medicinal composition for injections in articular cavity is provided.
Background technology:
Osteoarthritis is one of common clinically joint disease, is more common in the old people.Along with the prolongation of human average life and the continuous aggravation of aging society, the sickness rate of old people's osteoarthritis is also continuing rising, has seriously reduced old people's quality of life.Also therefore, arthritic treatment becomes the significant problem that needs to be resolved hurrily.
The osteoarthritis that a variety of causes causes all is from articular cartilage degeneration, and the change of sclerotin and synovial membrane takes place then, and the degeneration of cartilage comprises the change of chondrocyte and substrate.It is clinical mainly to show as cartilage destruction, disappearance, elasticity and weakens; The biological function lubricated and the opposing mechanism of knuckle synovia descends; Get involved etc. with synovitis, joint motion.
At present, for arthritic Drug therapy several different methods is arranged also, for example: control inflammation by giving glucocorticoid, but 2 distinct disadvantage of this method are: 1) though can cover arthritic pain symptom fast, amelioration of inflammation, but can not fundamentally improve the pathological changes of cartilage and knuckle synovia, the patient has often increased the weight of activity because of pain relief on the contrary, aggravated the lesion degree of cartilage and synovial fluid, arthritis is further increased the weight of; 2) glucocorticoid has tangible untoward reaction, has limited its application greatly.
From the eighties in last century, the viscoelasticity replacement therapy of osteoarthritis comes out, and promptly by intraarticular injection hyaluronate sodium (claiming hyaluronic acid sodium again) treatment osteoarthritis, and has obtained development of revolutionary significance.Hyaluronate sodium is as the important component part of knuckle synovia, the normal function of keeping synovial fluid is extremely important, make articular cartilage and synovial fluid have better elastic, in osteoarthritis patient's knuckle synovia, the molecular weight of hyaluronate sodium, concentration and viscoelasticity all obviously reduce, hyaluronate sodium by the son amount of directly awarding high marks in the articular cavity can directly improve knuckle synovia, and repairing articular cartilage progressively.The application of this method makes a lot of osteoarthritis patients obtain rehabilitation.Though can directly repair the cartilage of damage but use hyaluronate sodium separately, fundamentally treat osteoarthritis, reparation speed is slower, and the required course of treatment is longer.
Patent CN 02822420.5 and US2006003964 all disclose the arthritic method of drug treatment in hyaluronate sodium and the chondroitin sulfate use in conjunction articular cavity, and this method is the progress again on the basis of using hyaluronate sodium separately.But, and of the present inventionly discover the best results of hyaluronate sodium and chondroitin sulfate use in conjunction in specific molecular weight ranges in a large number according to the pathogenesis and the clinical manifestation of osteoarthritis.Because, chondroitin sulfate is the important substance that constitutes articular cartilage, chondroitin sulfate is as one of composition of cartilage, can participate in the structure of cartilage directly, quicken the regeneration and the reparation of cartilage, and can keep moisture, and make the nutritional labeling rapid osmotic to cartilage, this is extremely important to the cartilage that does not have blood supply.Articular cartilage absorbs ectogenic chondroitin sulfate, and progressively is converted into the part of articular cartilage self, and in this absorption process, the chondroitin sulfate of small-molecular weight is easier is relatively absorbed by cartilage.Having mentioned above for the hyaluronate sodium that is used for the treatment of osteoarthritis then requires molecular weight higher.
By last we as can be seen, hyaluronate sodium and chondroitin sulfate use in conjunction will reach optimum therapeuticing effect, then should satisfy following 2 points: 1) hyaluronate sodium must have higher molecular weight, has only this, could resist the obvious reduction of molecular weight, concentration and the viscoelasticity of hyaluronate sodium in the osteoarthritis patient knuckle synovia, recover the cushion pad and the lubrication of knuckle synovia; 2) chondroitin sulfate must have relatively low molecular weight, so that the treatment of osteoarthritis is accelerated in the fast Absorption of cartilage and reparation.The present invention has promptly proposed a kind of medicinal composition for injections in articular cavity on this research basis, met above-mentioned requirements.
Summary of the invention:
The invention provides a kind of medicinal composition for injections in articular cavity, the main component that it is characterized in that this pharmaceutical composition is hyaluronate sodium and chondroitin sulfate, wherein the molecular weight of hyaluronate sodium is 1,200,000～5,000,000 dalton, preferred 150～3,000,000 dalton, first-selected 150～2,000,000 dalton, the molecular weight of chondroitin sulfate is 2000～15000 dalton, preferred 4000～12000 dalton, first-selected 6000～8000 dalton.
The concentration of hyaluronate sodium is 0.5%～2.0% in the aforementioned pharmaceutical compositions, preferred 0.8%～1.2%, first-selected 1%.
The concentration of chondroitin sulfate is 1%～5% in the aforementioned pharmaceutical compositions, preferred 2%～3%, first-selected 2%.
Except that hyaluronate sodium and 2 kinds of main components of chondroitin sulfate, also contain the conventional dose adjuvant in the aforementioned pharmaceutical compositions, can be made into any dosage form that is used for intraarticular injection, first-selected liquid preparation and gel.
Aforementioned pharmaceutical compositions is used for drug treatment bone-specific drug arthritis in the articular cavity.
The consumption of aforementioned pharmaceutical compositions is: a drug dosage of each articular cavity is 1.5～3ml, preferred 2.0～2.5ml, first-selected 2.0ml.
Aforementioned pharmaceutical compositions is according to osteoarthritis conditions of patients difference, and its medicine frequency and cycle are: medication in per 5～8 days once, each treatment cycle was 3～8 weeks.
The pH scope of aforementioned pharmaceutical compositions is 6.5～7.5, and preferred pH scope is 6.8～7.4, and first-selected pH scope is 7.0～7.4; The osmotic pressure scope be 220～360 the milli ooze equivalent/liter, preferred 270～330 the milli ooze equivalent/liter.
The specific embodiment:
Embodiment 1: a kind of gel of articular cavity inner injecting and administering
Prescription:
Embodiment 3: a kind of liquid preparation of articular cavity inner injecting and administering
Prescription:
Embodiment 3: a kind of gel of articular cavity inner injecting and administering
Prescription:
Test data:
The effectiveness study of 1 pair of osteoarthritis of the embodiment of the invention
The preparation of 1 test specimen
1. test group: the embodiment of the invention 1.
2. contrast 1 group: get relative low-molecular-weight (800,000 dalton's) hyaluronate sodium 1g, relatively low-molecular-weight (8000 dalton) chondroitin sulfate 2g, all the other are with the embodiment of the invention 1.
3. contrast 2 groups: get relative low-molecular-weight (800,000 dalton's) hyaluronate sodium 1g, relatively high molecular (50000 dalton) chondroitin sulfate 2g, all the other are with the embodiment of the invention 1.
4. contrast 3 groups: get relative high molecular (1,500,000 dalton's) hyaluronate sodium 1g, relatively high molecular (50000 dalton) chondroitin sulfate 2g, all the other are with the embodiment of the invention 1.
5. negative control group: normal saline.
The grouping of 2 experimental animals
Get 40 of healthy new zealand white rabbits, body weight 2～3kg, male and female are not limit, and are divided into 5 groups at random: 1. test group; 2. contrast 1 group; 3. contrast 2 groups; 4. contrast 3 groups; 5. negative control group.
3 osteoarthritis Preparation of model and administrations
Cause the osteoarthritis varying model by injecting papain in the articular cavity, to injecting papain solution 0.1ml (the 1ml normal saline contains the 1.8mg papain, the 50mg cysteine) respectively in the right knee joint cavity of 5 groups of rabbits.After 3 days, inject again the 2nd time, inject altogether 2 times.After modeling the 7th day, 5 groups of test rabbits are injected above-mentioned sample 0.3ml in the same area of articular cavity respectively, 1 time weekly, totally 5 weeks.
The the gathering and processing and detecting of 4 samples
Rabbit is put to death in after last injection the 7th day.Scrape and get rabbit knee hair on every side, open the capable gross examination of skeletal muscle of articular cavity, complete then taking-up cartilage, major part are used for GAG content and measure (main component of cartilage glycosaminoglycans is a chondroitin sulfate, the content of the content direct reaction chondroitin sulfate of glycosaminoglycans), a small amount of cartilaginous tissue is fixed, dehydration routinely, paraffin embedding, the section of being cut into 5～6nm then, do HE, the dyeing of A Li Xinlan respectively, the section om observation.
5 results
1) according to Mankin osteoarthritis histologic classification method, cartilage is marked, the results are shown in Table 1.
Each animal groups knee cartilage om observation appraisal result of table 1
Each test group result is carried out statistical analysis to be shown: each administration group all has utmost point significant difference with negative control group, and wherein the integration of test group significantly is lower than each matched group, and therapeutic effect the best of the embodiment of the invention 1 is described.
2) adopt reddish black A method to measure the content of glycosaminoglycans, each is organized, and the content of glycosaminoglycans is converted into the contained sample size (x ± s), the results are shown in Table 2 of every 1mg cartilage weight in wet base in the sample.
The content of glycosaminoglycans in the table 2 different animals group knee cartilage
Each group result is carried out statistical analysis to be shown: test group, 3 matched groups are compared with negative control group, and significant difference is all arranged, and test group is compared with 3 matched groups and negative control group also all significant difference.Be the hyaluronate sodium and the chondroitin sulfate of same concentrations although show the main component of test group and 3 matched groups, but because of molecular weight need not, curative effect is also different, the test group embodiment of the invention 1 shows better therapeutic, what can alleviate cartilage moves back the change of shape property, and the content that effectively suppresses glycosaminoglycans in the cartilage reduces.
Claims (11)
1. a medicinal composition for injections in articular cavity is characterized in that this pharmaceutical composition contains hyaluronate sodium and chondroitin sulfate, and wherein the molecular weight of hyaluronate sodium is 150～2,000,000 dalton, and concentration is 0.5%～2.0%; The molecular weight of chondroitin sulfate is 6000～8000 dalton, and concentration is 1%～5%.
2. the described pharmaceutical composition of claim 1, the concentration that it is characterized in that hyaluronate sodium is 0.8%～1.2%.
3. the described pharmaceutical composition of claim 1, the concentration that it is characterized in that hyaluronate sodium is 1%.
4. the described pharmaceutical composition of claim 1, the concentration that it is characterized in that chondroitin sulfate is 2%～3%.
5. the described pharmaceutical composition of claim 1, the concentration that it is characterized in that chondroitin sulfate is 2%.
6. the arbitrary described pharmaceutical composition of claim 1-5 is characterized in that compositions is liquid preparation or gel.
7. the arbitrary described pharmaceutical composition of claim 1-5, the pH scope that it is characterized in that compositions is 6.5～7.5.
8. the described pharmaceutical composition of claim 7 is characterized in that described pH scope is 6.8～7.4.
9. the described pharmaceutical composition of claim 7 is characterized in that described pH scope is 7.0～7.4.
10. the arbitrary described pharmaceutical composition of claim 1-5, the osmotic pressure scope that it is characterized in that compositions be 220～360 millis ooze equivalent/liter.
11. the described pharmaceutical composition of claim 10, the osmotic pressure scope that it is characterized in that compositions be 270～330 the milli ooze equivalent/liter.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200610103473A CN100594029C (en) | 2006-07-24 | 2006-07-24 | Medicinal composition for injections in articular cavity |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200610103473A CN100594029C (en) | 2006-07-24 | 2006-07-24 | Medicinal composition for injections in articular cavity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101112381A CN101112381A (en) | 2008-01-30 |
| CN100594029C true CN100594029C (en) | 2010-03-17 |
Family
ID=39021009
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200610103473A Active CN100594029C (en) | 2006-07-24 | 2006-07-24 | Medicinal composition for injections in articular cavity |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100594029C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104027348A (en) * | 2010-12-28 | 2014-09-10 | 德普伊米特克公司 | Compositions and methods for treating joints |
| CN105982912A (en) * | 2015-03-02 | 2016-10-05 | 黄绣川 | Pharmaceutical composition containing sodium hyaluronate and chondroitin sulfate |
| US10532069B2 (en) | 2015-01-20 | 2020-01-14 | DePuy Synthes Products, Inc. | Compositions and methods for treating joints |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1394570B1 (en) * | 2009-07-02 | 2012-07-05 | Fidia Farmaceutici | BIOLOGICAL MATERIAL SUITABLE FOR THE OSTEOARTROSIS THERAPY OF TAPER DAMAGE AND FOR THE TREATMENT OF JOINT-PATHOLOGIES. |
| ITPD20120098A1 (en) * | 2012-03-30 | 2013-10-01 | Fidia Farmaceutici | "NEW PHARAMACEUTICAL FORMULATIONS CONTAINING CONDROITIN SULFATE AND DERIVATIVES OF HYALURONIC ACID" |
| ITMI20132116A1 (en) * | 2013-12-18 | 2015-06-19 | Apharm Srl | ASSOCIATION OF GLYCOSAMINOGLICANS AND CYCLODESTRINES |
| CN105920031A (en) * | 2016-04-21 | 2016-09-07 | 李媚 | Composition for joint repair and preparation method of composition |
| CN118902993A (en) * | 2016-04-25 | 2024-11-08 | 惠觅宙 | Application of injection containing small-molecule hyaluronic acid |
-
2006
- 2006-07-24 CN CN200610103473A patent/CN100594029C/en active Active
Non-Patent Citations (1)
| Title |
|---|
| 透明质酸与骨关节炎. 郑昱新，石印玉.Chinese J Trad Med Traum & Orthop.,Vol.7 No.4. 1999 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104027348A (en) * | 2010-12-28 | 2014-09-10 | 德普伊米特克公司 | Compositions and methods for treating joints |
| CN104027348B (en) * | 2010-12-28 | 2017-09-08 | 德普伊米特克公司 | Composition and method for treating joint |
| US11090328B2 (en) | 2010-12-28 | 2021-08-17 | Medos International Sarl | Compositions and methods for treating joints |
| US10532069B2 (en) | 2015-01-20 | 2020-01-14 | DePuy Synthes Products, Inc. | Compositions and methods for treating joints |
| CN105982912A (en) * | 2015-03-02 | 2016-10-05 | 黄绣川 | Pharmaceutical composition containing sodium hyaluronate and chondroitin sulfate |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101112381A (en) | 2008-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100594029C (en) | Medicinal composition for injections in articular cavity | |
| CN100571707C (en) | The articular cavity inner injecting and administering preparations that contains trehalose | |
| CN104689460B (en) | Scheme for intra-articular viscoplasticity supplement | |
| CN102630157A (en) | Injectable composition for intra-articular application combining a viscosity supplement and a fibroblast growth medium | |
| BR112019019743A2 (en) | botulinum neurotoxins for use in therapy | |
| US20050084518A1 (en) | Health food containing hyaluronic acid and dermatan sulfate | |
| Hakim et al. | Treatment of aseptic diseases of limb distal part joints in uzbek sport horses | |
| CN104707127A (en) | Chewable tablet used for relieving and preventing joint diseases and preparation method thereof | |
| CN1207022C (en) | Medicinal composition for promoting bone-fracture healing and bone-joint injure repairing | |
| CN105770850A (en) | Health care product for adjuvant treatment of osteoarticular diseases and preparation method of health care product | |
| US20200023044A1 (en) | Botulinum neurotoxins for treating traumatic injuries | |
| CN1771986A (en) | Orally taken joint function protectant | |
| CN102441023B (en) | Injection composition for treating orthopedic diseases | |
| CN105982911A (en) | Preparation method of high-viscoelasticity injection composed of glucosamine and sodium hyaluronate | |
| RU2268052C2 (en) | Agent for treatment of inflammatory and degenerative joint disease (variants), method for treatment of inflammatory and degenerative joint disease (variants) and device for delivery of medicinal agent to damaged site | |
| CN105796588B (en) | A kind of medicinal composition for injections in articular cavity containing Glucosamine | |
| CN101822827A (en) | Preparation for cosmetic dermatology and scar repairing | |
| CN104721805A (en) | Granules for alleviating and preventing joint diseases and preparation method thereof | |
| CN105267949A (en) | Medicine prescription for degenerative arthritis and osteoporosis and tablet preparation method thereof | |
| EP3448394B1 (en) | Compositions for use in treating tendon degeneration | |
| CN106267338A (en) | A kind of high persistency multiple-effect self-crosslinking fluid gel and preparation method and application | |
| CN112754981A (en) | Collagen regeneration promoting preparation and preparation method and application thereof | |
| CN1321692C (en) | Medicinal composition for treating arthritis | |
| RU2644724C1 (en) | Remedy with corrective effect on metabolism of cartilaginous tissue and method for its preparation | |
| CN113117144A (en) | Bionic dermis importing solution and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20190108 Address after: 250101 989 Xinjie street, Ji'nan high tech Zone, Shandong Patentee after: Pharmaceutical Sciences, Shandong Province Address before: 250014 No. 264 Shanda Road, Lixia District, Jinan City, Shandong Province Patentee before: Ling Peixue |
|
| TR01 | Transfer of patent right |